Charlottesville, Virginia: The bio-printing market will reach almost $112 million by 2020, and $307 million by 2023. This is according to a new report published by SmarTech Markets Publishing, an industry analyst firm. The report is entitled BIO-PRINTING MARKETS: A TEN-YEAR OPPORTUNITY FORECAST.

For more on the report, see: https://smartechpublishing.com/reports/bio-printing-markets-a-ten-year-opportunity-forecast

About the Report:

This report presents a thorough analysis of bio-printing markets including materials and software, as well as the printers themselves. Processes considered in this report include bio-plotting, inkjet, stereolithography, laser printing, laser direct write, acoustic droplet ejection, and magnetic levitation. The report also includes ten-year (volume and value) forecasts of several key bio-printing market segments including bio-printing labs, professional and compact bio-printers, bio-printing materials and bio-printing software. Bio-printing materials are broken out into biodegradable plastics, hydrogels and cell materials.

The report also discusses the product/market strategies of firms that are influential in bio-printing. These include Amira, AngioMix, ASI Life Sciences, Autodesk, Cook Biomedical, Drexel, EnvisionTEC, Fujifilm Dimatix, Lonza, Materialise, n3D Biosciences, nSkrypt, Organovo, Pharmacell, Regenovo, RoosterBio, Seraph, and TeVido BioDevices.

From the Report:

This report examines the commercialization potential for important bio-printing applications such drug testing and drug qualification, localized medicinal therapies, bio-pen applications, breast reconstruction and augmentation, partial organ therapies, and total organ replacement. It notes that these applications are likely to be commercialized at very different rate. Thus bio-printing for toxicology assays lie just one to two years away, while partial organ therapies are most likely to take more than a decade. There are also challenges to be overcome, such as difficulties with printing micro vascular structures to support larger tissues. In addition, many doctors remain skeptical whether commercial bio-printed products will be available soon.

Today, there are approximately 350 bio-printing labs worldwide, but this number will grow to over 1,000 by 2020. At present well over half of these labs are located in Europe, but by 2023, there will be as many bio-printing labs in Asia as in Europe. Lab count is important, since it is the primary driver for demand in equipment, materials, and software.

Sales of bio-printing equipment will reach almost $50 million by 2020 and more than $150 million by 2023. Down the road, commercial opportunities will merit the design of dedicated equipment for specific products. Also, SmarTech expects to see the emergence of compact bio-printers that will target small labs and academic institutions.

Meanwhile, software sales for bio-printing will reach $13.2 million by 2020 and $27.5 million by 2023. Existing software will most likely continue to adequately serve the needs of smaller labs for quite some time to come. But the expectation is that researchers – especially in larger labs — will shift towards more dedicated tools for bio-printing. The bio-printing materials market is projected to be nearly worth as much as the equipment market itself by 2023, helped by the fact that the cell demand will outpace the drop in material price over the next decade.

About SmarTech Markets Publishing:

SmarTech offers the best in industry analysis and forecasting for the 3D printing sector. Our published reports and customized consulting work provide clients with guidance on the direction that 3D printing is taking and how to capitalize on available opportunities. See www.smartechpublishing.com for more detail on our reports and other services.

For further information and for a complimentary extract of the report contact: Lawrence Gasman at [email protected] or 434-872-0450 (US)